Special Issue "Clinical Use of Botulinum Toxins"

Guest Editor
Prof. Dr. Bahman Jabbari
Department of Neurology, Yale University School of Medicine, New Haven, CT 06519, USA
E-Mail: bahman.jabbari@yale.edu

Dear Colleagues,

Introduction of Botulinum toxins(BoNTs) as therapeutic agents in clinical medicine have significantly improved management of involuntary movement disorders, debilitating spasticity and pain associated with a number of medical ailments. Animal data have shown that BoNTs do not only block the release of acetylcholine from presynaptic vesicles but also inhibit the release of a number of neurotransmitters and peptides most notable among them pain modulators (glutamate, substance P, calcitonin gene related peptide). The goal of this issue is to provide latest information about clinical utility of the BoNTs in clinical medicine. Those clinical conditions in which blinded and placebo controlled studies indicate efficacy is covered in details. The efficacy will be defined according to the guidelines of the American Academy of Neurology. The areas with potential efficacy based on smaller blinded studies or multiple prospective open observations will be mentioned briefly at the end of this issue.

The topics of this issue include: The molecular structure and mechanisms of action of botulinum toxins, blepharospasm, hemifacial spasm and facial dystonias, cervical dystonia and focal limb dystonia, headache and other pain disorders, conditions of increased muscle tone (spasicity and rigidity), genitourinary and gastrointestinal indications, orthopaedic indications , authonomic disorders (sialorhea and hyperhidrosis), tremors and tics, cosmetic indications, potential indications for future use.

Prof. Dr. Bahman Jabbari
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

• botulinum toxin
• pain
• headaches
• spasticiy
• dysonia
• sialorrhea
• hyperhidrosis
• blepharospasm
• hemifacial spasm
• tremor